The WACC of Centrexion Therapeutics Corp (CNTX) is 5.0%.
Range | Selected | |
Cost of equity | 5.4% - 7.3% | 6.35% |
Tax rate | 26.2% - 27.0% | 26.6% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 4.6% - 5.5% | 5.0% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 0.34 | 0.43 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 5.4% | 7.3% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 1 | 1 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 4.6% | 5.5% |
Selected WACC | 5.0% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
CNTX | Centrexion Therapeutics Corp | 1.19 | 1.15 | 0.62 |
APPB | Applied Biosciences Corp | 1772.92 | 0.22 | 0 |
BTHE | Boston Therapeutics Inc | 0.44 | 0.22 | 0.17 |
BVXV | BiondVax Pharmaceuticals Ltd | 1.06 | 1.83 | 1.03 |
ELAN | Elanco Animal Health Inc | 0.67 | 0.95 | 0.64 |
LLY | Eli Lilly and Co | 0.05 | 0.77 | 0.74 |
NBGV | NewBridge Global Ventures Inc | 0.14 | 0 | 0 |
NPTX | Neuropathix Inc | 67.83 | 1.83 | 0.04 |
PHBI | Pharmagreen Biotech Inc | 0.45 | -0.12 | -0.09 |
SNNAQ | Sienna Biopharmaceuticals Inc | 974603.7 | 0 | 0 |
TCDA | Tricida Inc | 20.35 | 0.21 | 0.01 |
Low | High | |
Unlevered beta | 0.01 | 0.17 |
Relevered beta | 0.01 | 0.15 |
Adjusted relevered beta | 0.34 | 0.43 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for CNTX:
cost_of_equity (6.35%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.34) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.